Slide 1: Simulations Plus, Inc. Third Quarter Fiscal Year 2009 Conference Call
Exhibit 99.1 Simulations Plus, Inc. NASDAQ: SLP Third Quarter Fiscal Year 2009 Conference Call July 16, 2009
Slide 2: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – Third Quarter FY 2009 (3QFY09) Financial Summary – Progress in Business Units – Strategy Going Forward – Questions and Answers
Slide 3: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 4: 3QFY09 (3 months) Financial Summary
3QFY09 (3 months) Financial Summary • Gross revenues = $2.713 MM (down 8.6% from 3QFY08) – Pharmaceutical software and services = $1.985 MM (up 0.5% from $1.975 MM in 3QFY08) – Words+ subsidiary = $728,000 (down 26.7% from $994,000 3QFY08) • SG&A = $989,000 (up 5.0% from $942,000 in 3QFY08) – Increa
Slide 5: 3QFY09 (9 months) Financial Summary
3QFY09 (9 months) Financial Summary • Gross revenues = $7.303 MM (up 2.4% from 9 months FY08) – Pharmaceutical software and services = $0.231 MM (up 4.7% from $4.963 MM in 9 months FY08) – Words+ subsidiary = $2.110 MM (down 2.7% from $2.169 MM in 9 months FY08) • SG&A = $2.929 MM (up 8.3% from $2.7
Slide 6: Share Repurchase Program
Share Repurchase Program • Board of directors authorized share repurchase program for up to $2.5 million from October 2008 through October 2009 • During 3QFY09, 172,978 shares were bought back at average price of about $1.02/share. As of July 10, over 648,000 shares bought back at average price per
Slide 7: Progress - 1
Progress - 1 • ADMET Predictor™ – Program was divided into modules with the last release • Requested by a number of smaller potential customers to reduce costs - appears to be a successful pricing strategy – New Dose Optimization Module determines dose amount needed for different new molecules based
Slide 8: Miner3D Graphics in ADMET Predictor 4.0
Miner3D™ Graphics in ADMET Predictor 4.0
Slide 9: Progress - 2
Progress - 2 • ClassPharmer™ – Continuing to enhance ability of ClassPharmer in data mining and de Novo molecule design (design of new molecules) – Presentation at a conference in London showing the power of ClassPharmer combined with ADMET Predictor for the automatic generation and screening of new
Slide 10: ClassPharmer Pair SAR ("Activity Cliffs") for hERG Toxicity
ClassPharmer Pair SAR (“Activity Cliffs”) for hERG Toxicity
Slide 11: Progress - 3
Progress - 3 • DDDPlus™ – Sales increasing steadily, with customers now in U.S., Europe, Japan, and India, including two licenses at the FDA – Version 3.0 released during Q3 - major update – Remains the only tool of its kind • GastroPlus™ – Development of Drug-drug Interaction module progressing ver
Slide 12: DDDPlus 3.0
DDDPlus 3.0 Simulates laboratory dissolution experiments
Slide 13: GastroPlus Ocular Delivery - Funded Collaboration
GastroPlus Ocular Delivery - Funded Collaboration
Slide 14: GastroPlus Pulmonary Delivery
GastroPlus Pulmonary Delivery
Slide 15: Progress - 4
Progress - 4 • Words+ subsidiary – General economy appears to be affecting this business - many states are struggling, and a large percentage of our sales come from 3rd-party sources (Medicaid, Medicare, schools, state vocational rehabilitation programs, etc.) – New Conversa™ communication device se
Slide 16: Miscellaneous
Miscellaneous • Potential acquisition we were working on for a number of months did not go through - - seller decided to go with another buyer. No news if that deal has been concluded. Potential remains to acquire software part of the business if the new buyerdiligence • Due is not interested initia
Slide 17: Strategy Going Forward
Strategy Going Forward • Continue to expand product line and services – Pharmaceutical software and services • Expand Life Sciences team by several scientists – For new product development as identified in corporate strategic planning – To increase capacity to conduct consulting studies and funded c
Slide 18: Summary
Summary • Simulations Plus financial strength continues – Excellent cash position that continues to grow – No debt – Share repurchase is gradually reducing number of shares outstanding without major impact to cash position • Decent third quarter - not outstanding, but in this economy, healthy – Phar
Slide 19: Impact Of Economic Environment
Impact Of Economic Environment • Budgets • Greater Tightening of R&D Budgets • Diminished Spending On Conference and Symposium Attendance By Prospect Organizations • Spending • Greater Justification Required For Any Type Of Spending • Organizations implementing Spending Increase Caps Of 4-7% • Appro
Slide 20: Questions?
Questions? simulations plus, inc. @&
Slide 21: Slide 21